 | Up a level |
Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H. A., Lamanna, N., Coiffier, B., Pettitt, A., Li, X., Jahn, T. M., O'Brien, S. M. and Hallek, M. J. (2014). SECOND INTERIM ANALYSIS OF A PHASE 3 STUDY EVALUATING IDELALISIB AND RITUXIMAB FOR RELAPSED CLL. Haematologica, 99. S. 249 - 251. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Eradat, H. A., Ghia, P., O'Brien, S. M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Cheson, B. D., Pagel, J. M., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Lamanna, N., Hallek, M. J., Coiffier, B., Pettitt, A., Kim, Y., Jahn, T. M. and Wagner, L. I. (2014). HEALTH-RELATED QUALITY OF LIFE IMPACT OF IDELALISIB (IDELA) IN PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PHASE 3 RESULTS. Haematologica, 99. S. 63 - 64. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Hallek, M., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I, Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Ruppert, S., Schuster, A. and Kroenig, H. (2014). 2nd analysis of a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib and Rituximab for previously treated patients with chronic lymphocytic leukemia. Oncol. Res. Treat., 37. S. 183 - 184. BASEL: KARGER. ISSN 2296-5262
Hallek, M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Pagel, J. M., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Cheson, B. D., Ruppert, S., Kroenig, H. and Schuster, A. (2014). Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL. Oncol. Res. Treat., 37. S. 52 - 54. BASEL: KARGER. ISSN 2296-5262
Munir, T., Hillmen, P., Eradat, H., Ghia, P., O'Brien, S., Furman, R., Coutre, S., Sharman, J., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Lamanna, N., Hallek, M., Coiffier, B., Pettitt, A., Kim, Y., Jahn, T. and Wagner, L. (2015). Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): phase 3 results. Br. J. Haematol., 169. S. 53 - 54. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141
Munir, T., Hillmen, P., Eradat, H., Ghia, P., O'Brien, S., Furman, R., Coutre, S., Sharman, J., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Lamanna, N., Hallek, M., Coiffier, B., Pettitt, A., Kim, Y., Jahn, T. and Wagner, L. (2015). Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): phase 3 results. Br. J. Haematol., 169. S. 53 - 54. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141